Management of Hypoglycemia in Patients with Type 2 Diabetes
Author:
Open Access
- 24 September 2018
- journal article
- Published by Lupine Publishers LLC in Archives of Diabetes & Obesity
- Vol. 1 (4) , 1-8
Abstract
The rate limiting step of intensive diabetes management for patients with diabetes is treatment induced hypoglycemia. Thus, hypoglycemia remains a significant barrierKeywords
This publication has 15 references indexed in Scilit:
- Efficacy and Safety of Degludec versus Glargine in Type 2 DiabetesNew England Journal of Medicine, 2017
- Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 DiabetesJAMA, 2017
- Cardiac Autonomic Regulation and Repolarization During Acute Experimental Hypoglycemia in Type 2 DiabetesDiabetes, 2017
- Patient‐level meta‐analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetesDiabetes, Obesity and Metabolism, 2015
- Low within‐ and between‐day variability in exposure to new insulin glargine 300 U/mlDiabetes, Obesity and Metabolism, 2015
- A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical RelevanceClinical Pharmacokinetics, 2014
- New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1Diabetes Care, 2014
- Does Glycemic Variability Impact Mood and Quality of Life?Diabetes Technology & Therapeutics, 2012
- Severe Hypoglycemia and Risks of Vascular Events and DeathNew England Journal of Medicine, 2010
- Reducing oxidative stress in patients with type 2 diabetes mellitus: A primary care call to actionInsulin, 2008